Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. [electronic resource]
Producer: 20070731Description: 1509-12 p. digitalISSN:- 0041-1337
- Adult
- Alemtuzumab
- Antibodies, Monoclonal -- adverse effects
- Antibodies, Monoclonal, Humanized
- Antibodies, Neoplasm -- adverse effects
- Antilymphocyte Serum
- Drug Therapy, Combination
- Female
- Follow-Up Studies
- Graft Rejection -- epidemiology
- Graft Survival
- Humans
- Immunosuppressive Agents -- therapeutic use
- Incidence
- Kidney Transplantation -- mortality
- Male
- Middle Aged
- Mycophenolic Acid -- therapeutic use
- Risk Factors
- Steroids -- therapeutic use
- Tacrolimus -- therapeutic use
- Transplantation Tolerance -- drug effects
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.